CD4 and HIV-1 infection: Nuclear coexistence between PKCθ and Tat during acute HIV-1 infection could be used as a therapeutic target because selective PKCθ inhibitors could disrupt this association and avoid the massive HIV-1 replication and CD4 depletion that occur during the first stages of the illness.